- Home
- MYSZ vs RDHL Comparison
MYSZ vs RDHL Comparison
Compare MYSZ & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYSZ
- RDHL
- Stock Information
- Founded
- MYSZ 1999
- RDHL 2009
- Country
- MYSZ Israel
- RDHL Israel
- Employees
- MYSZ N/A
- RDHL N/A
- Industry
- MYSZ Computer Software: Prepackaged Software
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- MYSZ Technology
- RDHL Health Care
- Exchange
- MYSZ Nasdaq
- RDHL Nasdaq
- Market Cap
- MYSZ 3.6M
- RDHL 3.9M
- IPO Year
- MYSZ N/A
- RDHL N/A
- Fundamental
- Price
- MYSZ $1.12
- RDHL $1.70
- Analyst Decision
- MYSZ Strong Buy
- RDHL
- Analyst Count
- MYSZ 1
- RDHL 0
- Target Price
- MYSZ $3.00
- RDHL N/A
- AVG Volume (30 Days)
- MYSZ 560.3K
- RDHL 43.1K
- Earning Date
- MYSZ 11-13-2025
- RDHL 09-05-2025
- Dividend Yield
- MYSZ N/A
- RDHL N/A
- EPS Growth
- MYSZ N/A
- RDHL N/A
- EPS
- MYSZ N/A
- RDHL N/A
- Revenue
- MYSZ $6,779,000.00
- RDHL $9,550,000.00
- Revenue This Year
- MYSZ $29.71
- RDHL $381.91
- Revenue Next Year
- MYSZ N/A
- RDHL N/A
- P/E Ratio
- MYSZ N/A
- RDHL N/A
- Revenue Growth
- MYSZ N/A
- RDHL 157.62
- 52 Week Low
- MYSZ $1.01
- RDHL $1.06
- 52 Week High
- MYSZ $9.40
- RDHL $11.70
- Technical
- Relative Strength Index (RSI)
- MYSZ 39.95
- RDHL 63.39
- Support Level
- MYSZ $1.09
- RDHL $1.47
- Resistance Level
- MYSZ $1.48
- RDHL $1.60
- Average True Range (ATR)
- MYSZ 0.07
- RDHL 0.09
- MACD
- MYSZ -0.01
- RDHL 0.04
- Stochastic Oscillator
- MYSZ 7.72
- RDHL 97.98
About MYSZ My Size Inc.
My Size Inc is a USA-based technology company that focuses on the development of an application that assists the consumer to accurately take the measurements of his or her own body to fit clothing without the need to try them on using a smartphone. The purpose of the company's business is to simplify the process of clothing acquisition through the Internet and to significantly reduce the rate of returns of clothing which were acquired through the internet and which are returned to the stores because of ill-fitting. The company generates its revenue through selling products to customers and licensing cloud-enabled software subscriptions, associated software maintenance, and support.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.